Jiejun J. Wang
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Health-related quality of life among anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients treated with first- and next-generation ALK tyrosine kinase inhibitors (TKIs): a systematic review and meta-analysis.
Journal: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
Published: April 08, 2025
Comparison of the Novel Digital Multi-dimension Botong Score with the Brief Pain Inventory for Evaluating Cancer-Related Pain: A Randomized Crossover Trial.
Journal: Pain and therapy
Published: June 07, 2023
Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer.
Journal: OncoTargets and therapy
Published: February 18, 2021
Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, Phase III trial.
Journal: Future oncology (London, England)
Published: December 16, 2020
UBE2C Is a Potential Biomarker of Intestinal-Type Gastric Cancer With Chromosomal Instability.
Journal: Frontiers in pharmacology
Published: May 10, 2018
A multi-center survey on dietary knowledge and behavior among inpatients in oncology department.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: September 27, 2017
Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer.
Journal: Investigational new drugs
Published: July 13, 2017
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin in Chinese patients with advanced and metastatic gastric cancer: Re-analysis of efficacy and safety data from the ML17032 phase III clinical trial.
Journal: Asia-Pacific journal of clinical oncology
Published: June 15, 2017
Increased SNAT1 is a marker of human osteosarcoma and potential therapeutic target.
Journal: Oncotarget
Published: March 10, 2017
Pyrophosphatase 1 expression is associated with future recurrence and overall survival in Chinese patients with intrahepatic cholangiocarcinoma.
Journal: Oncology letters
Published: July 31, 2016
Last Updated: 09/26/2026